Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Henry Schein, Inc. (HSIC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Henry Schein gains exclusive U.S. rights to Curodont, expanding its vVARDIS partnership and boosting expectations for a Dental business rebound.
HSIC gains momentum as Henry Schein One rolls out AI-powered dental workflows unveiled at the Greater New York Dental Meeting.
Henry Schein, Inc. ( HSIC ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:30 AM EST Company Participants Stanley Bergman - Executive Chairman & CEO Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Conference Call Participants Michael Sarcone - Jefferies LLC, Research Division Presentation Michael Sarcone Jefferies LLC, Research Division Hi, everyone. My name is Mike Sarcone.
Henry Schein, Inc. ( HSIC ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Tom Popeck - Chief Executive Officer of Henry Schein Products Group Ronald South - Senior VP & CFO Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Jonathan Block Stifel, Nicolaus & Company, Incorporated, Research Division I'm happy to introduce the team from Henry Schein. We have Ron South, CFO; Andrea Albertini, CEO of Global Distribution and Technology; and Tom Popeck, CEO of the Henry Schein Products Group.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Henry Schein, Inc. ( HSIC ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Stanley Bergman - Executive Chairman & CEO Ronald South - Senior VP & CFO Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division John Stansel - JPMorgan Chase & Co, Research Division Allen Lutz - BofA Securities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Michael Cherny - Leerink Partners LLC, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Brandon Vazquez - William Blair & Company L.L.C.
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein's Q3 earnings and revenues top estimates, lifting the stock as the company raised its 2025 outlook on solid business momentum.
Henry Schein (HSIC) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.22 per share a year ago.